Evaxion biotech announces publication of study on s. aureus bacterium in scientific reports

Copenhagen, denmark, march 16, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal scientific reports, describing a study into the bacterium staphylococcus aureus (s. aureus). the paper can be accessed here: www.nature.com/articles/s41598-021-84050-x
EVAX Ratings Summary
EVAX Quant Ranking